內科部

1. Cardiac tamponade as the first manifestation of gastric adenocarcinoma-Case repot and review of the literatures. Ming-En Liu et al, Acta Cardiol Sin 2000; 16:251-256
2. Subdural Hemorrhage in A Patient with Combined Aspirin and Clopidogrel Use - Case Report and Review of the Literature. Ming-En Liu et al. J Intern M ed Taiwan 2009; 20: 447-452
3. Obesity-Related Changes in Cardiac Structure and Function Among Asian Men and Women. Lai YH, Liu ME, Su CH, Yun CH, Liu CY, Hou CJ, Hu KC, Hung CL, Yeh HI, Lam CSP. J Am Coll Cardiol. 2017 Jun 13;69(23): 2876-2878
4. A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT). Koh KK, Nam CW, Chao TH, Liu ME, Wu CJ, Kim DS, Kim CJ, Li I, Li J, Baccara-Dinet MT, Hsiao PJ, Chiang CE. J Clin Lipidol. 2018 Jan - Feb;12(1):162-172.e6
5. A subanalysis of Taiwanese patients from ODYSSEY South Korea and Taiwan study evaluating the efficacy and safety of alirocumab. Chao TH, Hsiao PJ, Liu ME, Wu CJ, Chiang FT, Chen ZC, Chen CP, Yeh HI, Lee TH, Chiang CE. J Chin Med Assoc. 2019 Apr;82(4):265-271
6. Effects of lorcaserin on cardiometabolic risk factors in overweight and obese patients: A systematic review and meta-analysis. Kuo HH, Wang KT, Lee YH, Lin PL, Liu ME, Lin CY, Liu LY. J Clin Pharm Ther. 2020 Feb;45(1):35-44.
7. 2020 Consensus of Taiwan Society of Cardiology on the Pharmacological Management of Patients with Type 2 Diabetes and Cardiovascular Diseases Chiang, Chern-En; Ueng, Kwo-Chang; Chao, Ting-Hsing; Lin, Tsung-Hsien; Wu, Yih-Jer; Wang, Kang-Ling; Sung, Shih-Hsien; Yeh, Hung-I; Li, Yi-Heng; Liu, Ping-Yen; Chang, Kuan-Cheng; Shyu, Kou-Gi; Huang, Jin-Long; Tsai, Cheng-Dao; Hung, Huei-Fong; Liu, Ming-En; Chao, Tze-Fan; Cheng, Shu-Meng; Cheng, Hao-Min; Chu, Pao-Hsien; Yin, Wei-Hsian; Wu, Yen-Wen; Chen, Wen-Jone; Lai, Wen-Ter; Lin, Shing-Jong; Yeh, San-Jou; Hwang, Juey-Jen

參與國際大型臨床醫學試驗 Principle Investigator in Hsin-Chu MacKay Memorial Hospital

1. ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab
2. ODYSSEY KT: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy in South Korea and Taiwan
3. THEMIS: A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus(single site全球收案第2名)
4. ROSTAFUROXIN HT: Antihypertensive effect of different doses of ROSTAFUROXIN in comparison with Losartan, assessed by office and ambulatory blood pressure monitoring in a hypertensive population selected according to a specific genetic profile
5. VICTORIA: the VerICiguaT glObal study in patients with heart failure and Reduced ejectIon frAction study. (single site亞太地區收案第1名)
6. ENTRUST AF PCI: Evaluation of the safety and efficacy of an edoxaban-based compared to a vitamin K antagonist-based antithrombotic regimen following successful percutaneous coronary intervention (PCI) with stent placement. (single site全球收案第21名)
7. VOYAGER PAD: Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities
8. Dapa-HF: Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure (single site全球收案第16名, 亞太地區收案第1名)
9. PASSION: Patients' Assessment of Satisfaction for Stroke Prevention in Atrial Fibrillation Impact of Conventional Oral Anticoagulant (OAC) Compared with Novel Oral Anticoagulant (NOAC) (single site台灣收案第1名)
10. SELECT: Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity (single site台灣目前收案第1名)
11. DELIVER:Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure. (single site台灣目前收案第1名)
12. SCORED: Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk